Press Release

Remus Pharma reported strong FY26 consolidated results: Revenue ₹853.63 Cr (+37.6% YoY), EBITDA ₹56.69 Cr (+24.1%), PAT ₹46.17 Cr (+20.2%). The company significantly expanded its market presence, launched new products including Semaglutide, and achieved robust growth in its high-margin B2C segment.